<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence supports a role for <z:mp ids='MP_0003674'>oxidative stress</z:mp>, proinflammatory cytokines, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the pathophysiology of focal <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have found that the multi-action drug, <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, is a mixed <z:chebi fb="0" ids="37887">adrenergic antagonist</z:chebi>, and that it behaves as an <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and inhibits <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study, the authors investigated whether <z:chebi fb="0" ids="3441">carvedilol</z:chebi> provides protection in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and whether this protection is associated with <z:mp ids='MP_0006043'>reduced apoptosis</z:mp> and the downregulation of the inflammatory cytokines, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) and interleukin- 1beta (IL-1beta) </plain></SENT>
<SENT sid="3" pm="."><plain>Male Sprague-Dawley rats were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) by an intraluminal filament technique </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="3441">Carvedilol</z:chebi> (1, 3, and 10 mg/kg) was injected daily subcutaneously 2 or 4 days before the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Neurologic scores, <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes, TUNEL staining, and <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of TNF-alpha and IL-1beta were assessed at 24 hours reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>The effect of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> on microvascular cortical perfusion was studied with continuous laser-Doppler flowmetry </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-four hours after MCAO, <z:chebi fb="0" ids="3441">carvedilol</z:chebi> at <z:hpo ids='HP_0000001'>all</z:hpo> three doses reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes by at least 40% and reduced neurologic deficits on average by 40% compared with vehicle-treated controls when given 2 or 4 days before the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>This protection was not mediated by changes in temperature or blood flow </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment with <z:hpo ids='HP_0000001'>all</z:hpo> three dose regimens resulted in fewer TUNEL positive cells compared with controls </plain></SENT>
<SENT sid="10" pm="."><plain>At 24 hours reperfusion, <z:chebi fb="0" ids="3441">carvedilol</z:chebi> decreased TNF-alpha and IL-1beta expression by 40% to 50% in the ipsilateral ischemic cortex compared with the contralateral controls </plain></SENT>
<SENT sid="11" pm="."><plain>The results of the current study indicate that <z:chebi fb="0" ids="3441">carvedilol</z:chebi> is neuroprotective in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and may protect the ischemic brain by inhibiting <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and attenuating the expression of TNF-alpha and IL-1beta </plain></SENT>
</text></document>